{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:48:30Z","timestamp":1784177310045,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bneo.2025.100150","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T16:07:43Z","timestamp":1754323663000},"page":"100150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hypertension in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma in ALPINE: a secondary analysis"],"prefix":"10.1016","volume":"2","author":[{"given":"June-Wha","family":"Rhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3331-9491","authenticated-orcid":false,"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Aldairy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulce","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7310-8491","authenticated-orcid":false,"given":"William B.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bneo.2025.100150_bib1","article-title":"Imbruvica (ibrutinib). Package insert","year":"2024","journal-title":"Pharmacyclics LLC"},{"issue":"5","key":"10.1016\/j.bneo.2025.100150_bib2","first-page":"570","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"Cardio Oncology"},{"key":"10.1016\/j.bneo.2025.100150_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100150_bib4","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.3390\/ijms23052815","article-title":"Cardiotoxicity induced by protein kinase inhibitors in patients with cancer","volume":"23","author":"Grela-Wojewoda","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.bneo.2025.100150_bib5","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.bneo.2025.100150_bib6","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1182\/blood.V124.21.5657.5657","article-title":"An observational study of the occurrence of atrial fibrillation and hypertension in patients treated with ibrutinib","volume":"124","author":"Binsah","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bneo.2025.100150_bib7","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2025.100150_bib8","article-title":"Brukinsa (zanubrutinib). Package insert","year":"2024","journal-title":"BeiGene USA"},{"key":"10.1016\/j.bneo.2025.100150_bib9","article-title":"Calquence (acalabrutinib). Package insert","year":"2022","journal-title":"AstraZeneca Pharmaceuticals LP"},{"key":"10.1016\/j.bneo.2025.100150_bib10","article-title":"Jaypirca (pirtobrutinib). Package insert","year":"2023","journal-title":"LLC"},{"issue":"9","key":"10.1016\/j.bneo.2025.100150_bib11","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.bneo.2025.100150_bib12","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bneo.2025.100150_bib13","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/17512433.2021.1978288","article-title":"Clinical pharmacology and PK\/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib","volume":"14","author":"Tam","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.bneo.2025.100150_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221093980","article-title":"Zanubrutinib in lymphoproliferative disorders: a comprehensive review","volume":"13","author":"Mu\u00f1oz","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100150_bib15","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2021-148544","article-title":"Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (Pts) with relapsed\/refractory B-cell malignancies [abstract]","volume":"138","author":"Shadman","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2025.100150_bib16","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/bloodadvances.2023011641","article-title":"Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib","volume":"8","author":"Moslehi","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bneo.2025.100150_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bneo.2025.100150_bib18","article-title":"Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: Interim analysis of a randomized phase III trial","author":"Hillmen","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bneo.2025.100150_bib19","series-title":"Defining and validating chronic diseases: an administrative data approach","author":"Lix","year":"2006"},{"issue":"11","key":"10.1016\/j.bneo.2025.100150_bib20","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.mayocp.2024.05.029","article-title":"Increased risk of new-onset hypertension in patients with narcolepsy initiating sodium oxybate: a real-world study","volume":"99","author":"Ben-Joseph","year":"2024","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.bneo.2025.100150_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1161\/HYPERTENSIONAHA.109.139279","article-title":"Validation of a case definition to define hypertension using administrative data","volume":"54","author":"Quan","year":"2009","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.bneo.2025.100150_bib22","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100150_bib23","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1213\/ANE.0000000000003653","article-title":"Survival analysis and interpretation of time-to-event data: the tortoise and the hare","volume":"127","author":"Schober","year":"2018","journal-title":"Anesth Analg"},{"issue":"10285","key":"10.1016\/j.bneo.2025.100150_bib24","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","journal-title":"The Lancet"},{"issue":"38","key":"10.1016\/j.bneo.2025.100150_bib25","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.bneo.2025.100150_bib26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/europace\/eux091","volume":"19","author":"Lip","year":"2017","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.bneo.2025.100150_bib27","first-page":"179","article-title":"Predisposing factors for atrial fibrillation in the elderly","volume":"14","author":"Wasmer","year":"2017","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.bneo.2025.100150_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2020.100001","article-title":"Managing hypertension in the elderly: what\u2019s new?","volume":"1","author":"Aronow","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.bneo.2025.100150_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.769315","article-title":"Safety profile of ibrutinib: an analysis of the WHO pharmacovigilance database","volume":"12","author":"Allouchery","year":"2021","journal-title":"Front Pharmacol"},{"issue":"25","key":"10.1016\/j.bneo.2025.100150_bib30","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bneo.2025.100150_bib31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1253\/circj.CJ-17-0080","article-title":"Csk regulates blood pressure by controlling the synthetic pathways of aldosterone","volume":"82","author":"Kim","year":"2017","journal-title":"Circ J"},{"issue":"4","key":"10.1016\/j.bneo.2025.100150_bib32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bneo.2025.100150_bib33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"9735","key":"10.1016\/j.bneo.2025.100150_bib34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(10)60834-3","article-title":"Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study","volume":"376","author":"O'Donnell","year":"2010","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.bneo.2025.100150_bib35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCRESAHA.117.311402","article-title":"Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies","volume":"122","author":"Verdecchia","year":"2018","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.bneo.2025.100150_bib36","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/j.jemermed.2024.01.006","article-title":"Missed opportunities to diagnose and treat asymptomatic hypertension in emergency departments in the United States, 2016-2019","volume":"66","author":"Akhetuamhen","year":"2024","journal-title":"J Emerg Med"},{"key":"10.1016\/j.bneo.2025.100150_bib37","series-title":"Guideline for the pharmacological treatment of hypertension in adults","year":"2021"},{"issue":"17","key":"10.1016\/j.bneo.2025.100150_bib38","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1161\/CIRCULATIONAHA.112.096156","article-title":"Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010","volume":"126","author":"Gu","year":"2012","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.bneo.2025.100150_bib39","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1093\/ckj\/sfad195","article-title":"Management of hypertension in patients with cancer: challenges and considerations","volume":"16","author":"Pandey","year":"2023","journal-title":"Clin Kidney J"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:41:44Z","timestamp":1772923304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950328025000858"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100150","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertension in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma in ALPINE: a secondary analysis","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100150"}}